Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer

Mark W Burns, Eric S Kim Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Abstract: Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each year. Approximately 80% of lung can...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Burns MW, Kim ES
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/615bc03c1c684229b384790e7c3150d5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:615bc03c1c684229b384790e7c3150d5
record_format	dspace
spelling	oai:doaj.org-article:615bc03c1c684229b384790e7c3150d52021-12-02T00:43:10ZProfile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer1179-2728https://doaj.org/article/615bc03c1c684229b384790e7c3150d52015-05-01T00:00:00Zhttp://www.dovepress.com/profile-of-ceritinib-in-the-treatment-of-alk-metastatic-non-small-cell-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Mark W Burns, Eric S Kim Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Abstract: Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each year. Approximately 80% of lung cancer patients are diagnosed with non-small-cell lung cancer (NSCLC), a subset of epithelial lung cancers that are generally insensitive to chemotherapy. An estimated 3%–7% of NSCLC patients harbor tumors containing anaplastic lymphoma kinase (ALK) gene rearrangement as an oncogenic driver. Subsequent development of the first-generation tyrosine kinase inhibitor crizotinib demonstrated substantial initial ALK+-tumor regression, yet ultimately displayed resistance in treated patients. The recently approved tyrosine kinase inhibitor ceritinib has been shown to be an effective antitumor agent against crizotinib-naïve and -resistant ALK+-NSCLC patients. In this review, we will provide an overview of biology and management of ALK+-NSCLC with a special focus on clinical development of ceritinib. Keywords: ceritinib, anaplastic lymphoma kinase, non-small-cell lung cancerBurns MWKim ESDove Medical PressarticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol 2015, Iss default, Pp 35-42 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Burns MW Kim ES Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
description	Mark W Burns, Eric S Kim Wilmot Cancer Center, University of Rochester, Rochester, NY, USA Abstract: Lung cancer has become one of the leading causes of death in both men and women in the United States, with approximately 230,000 new cases and 160,000 deaths each year. Approximately 80% of lung cancer patients are diagnosed with non-small-cell lung cancer (NSCLC), a subset of epithelial lung cancers that are generally insensitive to chemotherapy. An estimated 3%–7% of NSCLC patients harbor tumors containing anaplastic lymphoma kinase (ALK) gene rearrangement as an oncogenic driver. Subsequent development of the first-generation tyrosine kinase inhibitor crizotinib demonstrated substantial initial ALK+-tumor regression, yet ultimately displayed resistance in treated patients. The recently approved tyrosine kinase inhibitor ceritinib has been shown to be an effective antitumor agent against crizotinib-naïve and -resistant ALK+-NSCLC patients. In this review, we will provide an overview of biology and management of ALK+-NSCLC with a special focus on clinical development of ceritinib. Keywords: ceritinib, anaplastic lymphoma kinase, non-small-cell lung cancer
format	article
author	Burns MW Kim ES
author_facet	Burns MW Kim ES
author_sort	Burns MW
title	Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
title_short	Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
title_full	Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
title_fullStr	Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
title_full_unstemmed	Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer
title_sort	profile of ceritinib in the treatment of alk+ metastatic non-small-cell lung cancer
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/615bc03c1c684229b384790e7c3150d5
work_keys_str_mv	AT burnsmw profileofceritinibinthetreatmentofalkmetastaticnonsmallcelllungcancer AT kimes profileofceritinibinthetreatmentofalkmetastaticnonsmallcelllungcancer
_version_	1718403499580981248

Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer

Ejemplares similares